ProtoKinetix, Inc. (PKTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US7437221002
ProtoKinetix, Inc. financials
| Fiscal year | 2025 |
|---|---|
| EBIT | -393,650.00 USD |
| Net income | -393,650.00 USD |
| Diluted EPS – continuing operations | 0.00 USD |
Full history since 2000, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ProtoKinetix, Inc.
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). Its AFGPs are used in various commercial applications, such as targeted health care solutions, as well as AAGPs are used in ophthalmology, dermatology, transplants, and biomanufacturing areas. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Dalton, Ohio.
More stocks
- GPO Plus, Inc. (GPOX)
- ORAGENICS INC (OGEN)
- Eline Entertainment Group, Inc. (EEGI)
- Adagio Medical Holdings, Inc. (ADGM)
- Nexentis Technologies Inc. (NXTS)
- Lunai Bioworks Inc. (LNAI)
- Cybin Inc (HELP.NE)
- Protagenic Therapeutics, Inc.\new (PTIX)
- CEMTREX INC (CETX)
- Mentor Capital, Inc. (MNTR)
- Karyopharm Therapeutics Inc. (KPTI)
- Catheter Precision, Inc. (VTAK)
Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.